Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director · Chief Executive Officer · 10% owner | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 905,993 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 6,893 · Balance 905,993 F1: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by Pardeep Nijhawan Medicine Professional Corporation | 402,702 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 402,702 F2: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by The New Nijhawan Family Trust 2015 | 32,609 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 32,609 F3: Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by The Digestive Health Clinic Inc. | 32,013 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 32,013 F2: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by 1968160Ontario Inc. | 53,104 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 53,104 F2: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
F2: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 21:05 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-006472 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905,993 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:12 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 5,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-005844 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,100 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 5,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-005208 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 893,386 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 21:05 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 3,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-004451 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888,062 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| June 16, 2026 Filed Jun 16, 2026 21:03 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 153,550 | $5.21 | $799,995.50 |
DisclosureSEC source: 0001171843-26-004151 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,684 F1 · shares: On June 16, 2026, the Reporting Person purchased in a private placement, 153,550 shares of the Issuer's common shares, at a purchase price of $5.21 per share, for an aggregate purchase price of $799,995.50. F1 · price: On June 16, 2026, the Reporting Person purchased in a private placement, 153,550 shares of the Issuer's common shares, at a purchase price of $5.21 per share, for an aggregate purchase price of $799,995.50. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 21:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 1,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003842 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,134 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 96,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003797 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,463 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-002942 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,550 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| April 01, 2026 Filed Apr 10, 2026 21:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-002373 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,391 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| March 10, 2026 Filed Mar 10, 2026 21:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,000 | $6.60 | $6,598.90 |
DisclosureSEC source: 0001171843-26-001463 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,813 Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 10,000 | $3.90 | $39,000.00 |
DisclosureSEC source: 0001171843-26-001390 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 402,702 F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 10,000 | $4.26 | $42,560.00 |
DisclosureSEC source: 0001171843-26-001370 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 392,702 F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 10,000 | $3.63 | $36,300.00 |
DisclosureSEC source: 0001171843-26-001329 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 382,702 F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:05 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 10,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-001267 · ownership.xml · nonDerivative · entry 2 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,813 F2 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 22:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,000 | $2.28 | $2,279.60 |
DisclosureSEC source: 0001171843-26-001302 · ownership.xml · nonDerivative · entry 2 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 372,702 F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 22:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 2,000 | $2.00 | $4,000.00 |
DisclosureSEC source: 0001171843-26-001302 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,813 Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:05 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 30,000 | $2.22 | $66,696.00 |
DisclosureSEC source: 0001171843-26-001267 · ownership.xml · nonDerivative · entry 3 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 371,702 F3 · price: The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.22 to $2.2295 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:05 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 20,571 | $1.58 | $32,479.55 |
DisclosureSEC source: 0001171843-26-001267 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,797 F1 · price: The price reported in this Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Mar 2, 2026 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 82,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-001266 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,226 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2025. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2025. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 11,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-000567 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,990 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 10,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-000069 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,822 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 23:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 8,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-007725 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,378 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 23:13 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-007107 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,612 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:31 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 5,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-006274 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,644 F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| September 11, 2025 Filed Sep 13, 2025 01:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 5,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-005895 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,736 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 01:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-005016 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463,755 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 01:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 7,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-004300 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,953 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 01:21 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 7,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003590 · ownership.xml · nonDerivative · entry 2 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,767 F4 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F4 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:21 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 263,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003590 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,123 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 166,287 shares shall vest monthly in equal proportions over twelve (12) months, commencing on the grant date and (ii) 96,913 shares shall vest in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 166,287 shares shall vest monthly in equal proportions over twelve (12) months, commencing on the grant date and (ii) 96,913 shares shall vest in equal proportions over thirty-six (36) months, commencing on the grant date. Read SEC document |
| May 02, 2025 Filed May 6, 2025 21:28 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-002829 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,923 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:25 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 5,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001997 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,531 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 01:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001217 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,747 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantSeries B-1 Convertible Preferred Shares · Derivative | 100 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001171843-25-000868 · ownership.xml · derivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100 Underlying: Common Shares · 520,833 shares Expires not disclosed F3 · price: On February 11, 2025, the Reporting Person purchased in a private placement, 100 shares of the Issuer's newly designated Series B-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share for an aggregate purchase price of $1.0 million. The Preferred Shares are immediately convertible at $1.92 per share, to the extent that after giving effect to such conversion the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. F1 · derivative.expiration_date: The Preferred Shares are perpetual and therefore have no expiration date. F2 · derivative.underlying_shares: Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus all other amounts due in respect of such Preferred Share (excluding distributions), by the conversion price at the time of conversion. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 00:32 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 8,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-000620 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,408 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| January 06, 2025 Filed Jan 6, 2025 23:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 8,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-000056 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,144 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 02:08 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 6,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-006707 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,668 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 02:29 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 4,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-006302 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,248 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| October 30, 2024 Filed Nov 2, 2024 00:49 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantWarrants (right to buy) · Derivative | 326,560 | Not disclosed Strike: $3.45 | Not disclosed |
DisclosureSEC source: 0001171843-24-005964 · ownership.xml · derivative · entry 2 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 326,560 Underlying: Common Stock · 326,560 shares Expires 2029-10-30 F3 · price: On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at $3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of $10,272.13. F4 · ownership.nature: Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2024 Filed Nov 2, 2024 00:49 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantSeries A-1 Convertible Preferred Shares · Derivative | 150 | Not disclosed Strike: $3.45 | Not disclosed |
DisclosureSEC source: 0001171843-24-005964 · ownership.xml · derivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 150 Underlying: Common Stock · 435,414 shares Expires not disclosed F3 · price: On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at $3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of $10,272.13. F1 · derivative.expiration_date: The Preferred Shares are perpetual and therefore have no expiration date. F2 · derivative.underlying_shares: Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus any accrued and unpaid dividends, by the conversion price at the time of conversion. Until the three-year anniversary of the day of issuance, holders of Preferred Shares are entitled to an annual return equal to 10% of the stated value per Preferred Share payable by the issuance of common shares at the conversion price upon a buy-back by the Issuer, liquidation or on conversion at the conversion price (calculated daily). F4 · ownership.nature: Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 01:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-005464 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,618 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 00:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 3,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-005045 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,318 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| August 01, 2024 Filed Aug 3, 2024 01:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 3,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-004413 · ownership.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,263 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| July 02, 2024 Filed Jul 4, 2024 01:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 4,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-008617 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,946 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 01:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 4,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-007354 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,931 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| May 01, 2024 Filed May 2, 2024 01:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share | 3,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-005413 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,146 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 23:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-004189 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,063 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| March 25, 2024 Filed Mar 25, 2024 19:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001654954-24-003606 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner Pardeep Nijhawan Medicine Professional Corp · CIK 0001780021 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 341,702 F1 · ownership.nature: Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:20 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-002509 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,810 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 02:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-001264 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,045 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Read SEC document |
| January 08, 2024 Filed Jan 12, 2024 22:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-24-000528 · section16.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,067 F1 · shares: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F1 · price: Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. F2 · balance_after: Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.